SuperworthLigand Pharmaceuticals shares outstanding LGND
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 21.8M
- On a year earlier
- +9.6%
- more shares
Ligand Pharmaceuticals had 21.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 9.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 20.7M | +9% |
| FY2024 | 19M | +7% |
| FY2023 | 17.7M | +5% |
| FY2022 | 16.9M | +1% |
| FY2021 | 16.7M | +0% |
| FY2020 | 16.7M | −3% |
| FY2019 | 17.2M | −18% |
| FY2018 | 21.1M | −0% |
| FY2017 | 21.1M | +1% |
| FY2016 | 20.9M | −3% |
| FY2015 | 21.5M | +4% |
| FY2014 | 20.8M | −1% |
| FY2013 | 21.1M | +5% |
| FY2012 | 20.1M | +2% |
| FY2011 | 19.8M | +1% |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 21.8M | +10% | |
| Q1 FY26 | 19.9M | +4% | |
| Q4 FY25 | 20.7M | +9% | |
| Q3 FY25 | 20.6M | +12% | |
| Q2 FY25 | 19.9M | +11% | |
| Q1 FY25 | 19.2M | +6% | |
| Q4 FY24 | 19M | +7% | |
| Q3 FY24 | 18.4M | +6% | |
| Q2 FY24 | 18M | +2% | |
| Q1 FY24 | 18.1M | +1% | |
| Q4 FY23 | 17.7M | +5% | |
| Q3 FY23 | 17.4M | +1% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Ligand Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.